(EN) Richard Finkel, Michelle Alexia Clark, Pamela C. Champe, Luigi X. Cubeddu, Pharmacology, Lippincott Williams & Wilkins, 1º luglio 2008, p. 165, ISBN978-0-7817-7155-9.
S. Mercadante, Opioid rotation for cancer pain: rationale and clinical aspects., in Cancer, vol. 86, n. 9, novembre 1999, pp. 1856-66, PMID10547561.
Mercadante S, Ferrera P, Villari P, Adile C, Casuccio A., Switching from oxycodone to methadone in advanced cancer patients, in Supportive Care in Cancer, vol. 20, n. 1, luglio 2011, pp. 191-194, PMID21901297.
Gensini GF., New disposition for pain therapy in Italy, center for headache should be integrated in the network, in Neurological Sciences, vol. 32, maggio 2011, p. 67-70, PMID21533716.
de Castro A, Jones HE, Johnson RE, Gray TR, Shakleya DM, Huestis MA, Maternal methadone dose, placental methadone concentrations, and neonatal outcomes, in Clinical Chemistry 2011, vol. 57, gennaio 2011, pp. 449-458, PMID21245372.
Glatstein MM, Garcia-Bournissen F, Finkelstein Y, Koren G, Methadone exposure during lactation, in College of Family Physicians of Canada, dicembre 2008, PMID19074706.
Kell MJ, Utilization of plasma and urine methadone concentrations to optimize treatment in maintenance clinics: I. Measurement techniques for a clinical setting, in Journal of addictive diseases: the official journal of the ASAM, American Society of Addiction Medicine, vol. 13, n. 1, 1994, pp. 5–26, PMID8018740.
Eap CB, Buclin T, Baumann P, Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence, in Clinical pharmacokinetics, vol. 41, n. 14, 2002, pp. 1153–93, PMID12405865.
Lynn RK, Olsen GD, Leger RM, Gordon WP, Smith RG, Gerber N, The secretion of methadone and its major metabolite in the gastric juice of humans: comparison with blood and salivary concentrations, in Drug Metab. Dispos., vol. 4, n. 5, 1976, pp. 504–9, PMID10151.
Armstrong SC, Cozza KL, Med-psych drug-drug interactions update, in Psychosomatics, vol. 43, n. 2, 2002, pp. 169–70, PMID11998586.
(LT) Reingardiene D, Jodziūniene L, Lazauskas R, [Methadone treatment and its dangers], in Medicina (Kaunas), vol. 45, n. 5, 2009, pp. 419–25, PMID19535889.
Vetulani J, Drug addiction. Part III. Pharmacotherapy of addiction, in Pol J Pharmacol, vol. 53, n. 5, 2001, pp. 415–34, PMID11990060.
Davis AM, Inturrisi CE, d-Methadone blocks morphine tolerance and N-methyl-D-aspartate-induced hyperalgesia, in J. Pharmacol. Exp. Ther., vol. 289, n. 2, maggio 1999, pp. 1048–53, PMID10215686.
Inturrisi CE, Pharmacology of methadone and its isomers, in Minerva Anestesiol, vol. 71, n. 7-8, 2005, pp. 435–7, PMID16012416.
Shah S, Diwan S, Methadone: does stigma play a role as a barrier to treatment of chronic pain?, in Pain Physician, vol. 13, n. 3, 2010, pp. 289–93, PMID20495594.
Santiago-Palma J, Khojainova N, Kornick C, et al., Intravenous methadone in the management of chronic cancer pain: safe and effective starting doses when substituting methadone for fentanyl, in Cancer, vol. 92, n. 7, ottobre 2001, pp. 1919–25, PMID11745266.
(ES) Prieto-Alvarez MP, Fuentes-Bellido JG, López-Cebollada J, Lorenzo-Foz JP, [Comparative study of postoperative analgesia with methadone and fentanyl in continuous peridural perfusion], in Rev Esp Anestesiol Reanim, vol. 44, n. 8, ottobre 1997, pp. 305–9, PMID9424683.
Eap CB, Bertschy G, Powell K, Baumann P, Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone, in J Clin Psychopharmacol, vol. 17, n. 2, aprile 1997, pp. 113–7, PMID10950475.
Iribarne C, Picart D, Dréano Y, Berthou F, In vitro interactions between fluoxetine or fluvoxamine and methadone or buprenorphine, in Fundam Clin Pharmacol, vol. 12, n. 2, 1998, pp. 194–9, PMID9565774.
Baumann P, Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors, in Clin Pharmacokinet, vol. 31, n. 6, dicembre 1996, pp. 444–69, PMID8968657.
(ES) Moreno Brea MR, Rojas Corrales O, Gibert-Rahola J, Micó JA, [Drug interactions of methadone with CNS-active agents], in Actas Esp Psiquiatr, vol. 27, n. 2, 1999, pp. 103–10, PMID10380152.
Esteban J, Pellín Mde L, Gimeno C, et al., Increase of R-/S-methadone enantiomer concentration ratio in serum of patients treated with either nevirapine or efavirenz, in Drug Metab Lett, vol. 2, n. 4, dicembre 2008, pp. 269–79, PMID19356104.
Manfredi R, Calza L, Chiodo F, Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study, in J. Acquir. Immune Defic. Syndr., vol. 35, n. 5, aprile 2004, pp. 492–502, PMID15021314.
Keller GA, Ponte ML, Di Girolamo G, Other drugs acting on nervous system associated with QT-interval prolongation, in Curr Drug Saf, vol. 5, n. 1, gennaio 2010, pp. 105–11, PMID20210727.
Gongadze N, Kezeli T, Antelava N, Prolong QT interval and "torsades de pointes" associated with different group of drugs, in Georgian Med News, n. 153, dicembre 2007, pp. 45–9, PMID18250496.
L. Nicholls, L. Bragaw; C. Ruetsch, Opioid dependence treatment and guidelines., in J Manag Care Pharm, vol. 16, 1 Suppl B, febbraio 2010, pp. S14-21, PMID20146550.
Nicholls L, Bragaw L, Ruetsch C, Opioid dependence treatment and guidelines, in J Manag Care Pharm, vol. 16, 1 Suppl B, febbraio 2010, pp. S14–21, PMID20146550.
M. Connock, A. Juarez-Garcia; S. Jowett; E. Frew; Z. Liu; RJ. Taylor; A. Fry-Smith; E. Day; N. Lintzeris; T. Roberts; A. Burls, Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation., in Health Technol Assess, vol. 11, n. 9, marzo 2007, pp. 1-171, iii-iv, PMID17313907.
H. Joseph, S. Stancliff; J. Langrod, Methadone maintenance treatment (MMT): a review of historical and clinical issues., in Mt Sinai J Med, vol. 67, n. 5-6, pp. 347-64, PMID11064485.